Being developed as the first GalNAc-siRNA drug based on our proprietary liver-targeting delivery technology RiboGalSTAR^TM for the treatment of Hepatitis B, RBD1016 covers patient population with hepatitis B virus genotypes A-E and I in Europe, the United States and Asia. In phase II clinical studies, RBD1016 has demonstrated well tolerated safety as well as strong and up to 6-month long-lasting inhibitory effect on HBsAg. Therefore, RBD1016 can serve as a cornerstone therapy in future combination approaches to achieve functional cure for CHB and a leading siRNA candidate for CHD.

A Phase Ia study in Australia and a Phase Ib study in Hong Kong have been completed.  RBD1016's Phase Ⅱ global multi-regional clinical trial (MRCT) for treating CHB is ongoing in Sweden and Hong Kong. A Phase IIa clinical trial application for Hepatitis D patients was approved by the EMA, with the study ongoing and participant enrollment completed.

Being developed as the first GalNAc-siRNA drug based on our proprietary liver-targeting delivery technology RiboGalSTAR^TM for the treatment of Hepatitis B, RBD1016 covers patient population with hepatitis B virus genotypes A-E and I in Europe, the United States and Asia. In phase II clinical studies, RBD1016 has demonstrated well tolerated safety as well as strong and up to 6-month long-lasting inhibitory effect on HBsAg. Therefore, RBD1016 can serve as a cornerstone therapy in future combination approaches to achieve functional cure for CHB and a leading siRNA candidate for CHD.

A Phase Ia study in Australia and a Phase Ib study in Hong Kong have been completed.  RBD1016's Phase Ⅱ global multi-regional clinical trial (MRCT) for treating CHB is ongoing in Sweden and Hong Kong. A Phase IIa clinical trial application for Hepatitis D patients was approved by the EMA, with the study ongoing and participant enrollment completed.